IMUGENE LIMITED — Director's Dealing 2022

Nov 8, 2022

==> picture [177 x 30] intentionally omitted <==

ASX Announcement

Non-Executive Directors increase shareholding following option exercise

---

SYDNEY, Australia, 9 November 2022: Imugene Limited (Company) (ASX:IMU) advises that the following Non-Executive Directors have increased their shareholdings in the Company as follows:

• Dr Jens Eckstein elected to exercise 10 million options ahead of expiry on 8 November 2022 to increase his shareholding in the Company to 20.5 million shares; and

• Mr Charles Walker elected to exercise 25 million options ahead of expiry on 8 November 2022 to increase his shareholding in the Company to 22.57 million shares.

In both cases the option exercise costs were covered by the net proceeds of share disposals. Further details are available in the attached Appendix 3Ys for Dr Eckstein and Mr Walker following the above changes.

-END-

Release authorised by the Company Secretary

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Imugene Limited (ASX:IMU)
Name of Entity:
	99 009 179 551
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr Jens Eckstein
Date of Last Notice:	9 February 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		N/A
Date of change		2 to 3 November 2022
No. of securities held prior to change				Options 10,000,000 - 10,000,000
			Shares	Options
		Direct	12,900,000	10,000,000
		Indirect	-	-
		Total	12,900,000	10,000,000
Class		Fully Paid Ordinary Shares Unlisted Options		(IMU) and
Number acquired				Options - - -
			Shares	Options
		Direct	a) 10,000,000	-
		Indirect	-	-
		Total	10,000,000	-
Number disposed				Options a) 10,000,000 - 10,000,000
			Shares	Options
		Direct	b) 2,400,000	a) 10,000,000
		Indirect	-	-
		Total	2,400,000	10,000,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		a) $0.045 per share b) $0.1925 per share	a) $0.045 per share b) $0.1925 per share
No. of securities held after change				Options - - -
			Shares	Options
		Direct	20,500,000	-
		Indirect	-	-
		**Total **	20,500,000	-
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back		a) Exercise of Options. b) On-Market Trade.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Imugene Limited (ASX: IMU)
Name of Entity:
	99 009 179 551
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Charles Walker
Date of Last Notice:	14 June 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Director related entity.
Date of change		2 to 4 November 2022
No. of securities held prior to change				Options - 25,006,669 25,006,669
			Shares	Options
		Direct	2,295,817	-
		Indirect	3,525,210	25,006,669
		Total	5,821,027	25,006,669
Class		Fully Paid Ordinary Shares Unlisted Options		(IMU) and
Number acquired				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	(a) 5,000,000 (b) 10,000,000 (c)10,000,000	-
		Total	25,000,000	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - (a) 5,000,000 (b) 10,000,000 (c) 10,000,000 25,000,000
			Shares	Options
		Direct	-	-
		Indirect	(d) 8,250,000	(a) 5,000,000 (b) 10,000,000 (c) 10,000,000
		**Total **	8,250,000	25,000,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		a) $0.040 per share b) $0.042 per share c) $0.045 per share d) Between $0.1950 and $0.1952 per share
No. of securities held after change				Options - 6,669 6,669
			Shares	Options
		Direct	2,295,817	-
		Indirect	20,275,210	6,669
		**Total **	22,571,027	6,669
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back		a), b) & c) Exercise of Options. d) On-Market Trade.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3